Cover Image
市場調查報告書

PharmaPoint:帕金森氏症 - 現在·未來市場參與企業

PharmaPoint: Parkinson's Disease - Current and Future Players

出版商 GlobalData 商品編碼 302383
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:帕金森氏症 - 現在·未來市場參與企業 PharmaPoint: Parkinson's Disease - Current and Future Players
出版日期: 2014年03月31日 內容資訊: 英文 57 Pages
簡介

本報告提供全球帕金森氏症相關市場上的現有企業及新加入企業相關分析,提供今後的整體市場預測和促進·阻礙因素,現在·未來的競爭方案,再加上主要企業簡介(營業內容,策略,業績·財務實際成果,競爭力)等調查資料·考察,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 本報告概要
  • 相關調查

第3章 市場預測

  • 全球市場
    • 未來預測
    • 市場促進·阻礙因素:全世界的課題

第4章 現在·未來市場參與企業

  • 概要
  • 企業策略的趨勢
  • 企業簡介
    • Merck
    • Roche
    • AbbVie
    • UCB
    • GlaxoSmithKline
    • Novartis
    • Orion
    • Newron
    • Civitas
    • Impax
    • Lundbeck

第5章 附錄

圖表一覽

目錄
Product Code: GDHC1033FPR

GlobalData has released its pharma report, "PharmaPoint: Parkinson's Disease - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Parkinson's Disease Market. The report identifies and analyses the key companies shaping and driving the global Parkinson's Disease market. The report provides insight into the competitive Parkinson's Disease landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Parkinson's Disease
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Parkinson's Disease sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Parkinson's Disease market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Parkinson's Disease market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Merck
    • 4.3.2. Roche
    • 4.3.3. AbbVie
    • 4.3.4. UCB
    • 4.3.5. GlaxoSmithKline
    • 4.3.6. Novartis
    • 4.3.7. Orion
    • 4.3.8. Newron
    • 4.3.9. Civitas
    • 4.3.10. Impax
    • 4.3.11. Lundbeck

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Diagnosed Parkinson's disease Patients
    • 5.4.2. Percent Drug-Treated Patients
    • 5.4.3. General Pricing Assumptions
    • 5.4.4. Compliance Assumptions
    • 5.4.5. Generic Erosion
  • 5.5. Physicians and Specialists Included in this Study
  • 5.6. About the Authors
    • 5.6.1. Author
    • 5.6.2. Global Head of Healthcare
  • 5.7. About GlobalData
  • 5.8. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($m) for Parkinson's Disease, 2012-2022
  • Table 2: Parkinson's Disease Market - Drivers and Barriers, 2012-2022
  • Table 3: Key Companies in the Parkinson's Market, 2014
  • Table 4: Merck's Parkinson's Disease Portfolio Assessment, 2014
  • Table 5: Merck's PD SWOT Analysis, 2014
  • Table 6: Roche's Parkinson's Disease Portfolio Assessment, 2014
  • Table 7: Roche's PD SWOT Analysis, 2014
  • Table 8: AbbVie's Parkinson's Disease Portfolio Assessment, 2014
  • Table 9: AbbVie's PD SWOT Analysis, 2014
  • Table 10: UCB's Parkinson's Disease Portfolio Assessment, 2014
  • Table 11: UCB's PD SWOT Analysis, 2014
  • Table 12: GSK's Parkinson's Disease Portfolio Assessment, 2014
  • Table 13: GSK's PD SWOT Analysis, 2014
  • Table 14: Novartis' Parkinson's Disease Portfolio Assessment, 2014
  • Table 15: Novartis' PD SWOT Analysis, 2014
  • Table 16: Orion's Parkinson's Disease Portfolio Assessment, 2014
  • Table 17: Orion's PD SWOT Analysis, 2014
  • Table 18: Newron's Parkinson's Disease Portfolio Assessment, 2014
  • Table 19: Newron's PD SWOT Analysis, 2014
  • Table 20: Civitas' Parkinson's Disease Portfolio Assessment, 2014
  • Table 21: Civitas' PD SWOT Analysis, 2014
  • Table 22: Impax's Parkinson's Disease Portfolio Assessment, 2014
  • Table 23: Impax's PD SWOT Analysis, 2014
  • Table 24: Lundbeck's Disease/Therapy Portfolio Assessment, 2014
  • Table 25: Lundbeck's SWOT Analysis, 2014

List of Figures

  • Figure 1: Global Sales for Parkinson's Disease by Region, 2012-2022
  • Figure 2: Company Portfolio Gap Analysis in Parkinson's Motor Symptoms, 2012-2022
Back to Top